KALA BIO, Inc. (FRA:27F0)

Germany flag Germany · Delayed Price · Currency is EUR
1.128
+0.397 (54.31%)
Last updated: Dec 1, 2025, 3:56 PM CET
-80.59%
Market Cap6.84M
Revenue (ttm)n/a
Net Income (ttm)-30.55M
Shares Outn/a
EPS (ttm)-4.96
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,485
Average Volume50
Open0.802
Previous Close0.731
Day's Range0.802 - 1.250
52-Week Range0.512 - 16.990
Betan/a
RSI37.18
Earnings DateMar 27, 2026

About KALA BIO

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company’s lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, In... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2009
Employees 38
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 27F0
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.